A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for approximately 2 years after initial administration, aligning with outcomes in ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, but not longer, follow-ups. The benefits of bevacizumab (Avastin) for the ...